MicroRNA transcriptome profiling in cardiac tissue of hypertrophic cardiomyopathy patients with MYBPC3 mutations.
暂无分享,去创建一个
F. T. ten Cate | C. D. dos Remedios | C. Oudejans | M. Michels | D. Kuster | J. van der Velden | P. A. da Costa Martins | J. Mulders
[1] P. Elliott,et al. Cardiac Myosin Binding Protein-C Mutations in Families With Hypertrophic Cardiomyopathy: Disease Expression in Relation to Age, Gender, and Long Term Outcome , 2012, Circulation. Cardiovascular genetics.
[2] C. Fishwick,et al. Pregnenolone sulphate-independent inhibition of TRPM3 channels by progesterone , 2012, Cell calcium.
[3] E. R. Paalberends,et al. Contractile Dysfunction Irrespective of the Mutant Protein in Human Hypertrophic Cardiomyopathy With Normal Systolic Function , 2012, Circulation. Heart failure.
[4] M. Link,et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.
[5] A. Wilde,et al. Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction , 2011, European journal of heart failure.
[6] D. Kuster,et al. Cardiac myosin binding protein C phosphorylation in cardiac disease , 2011, Journal of Muscle Research and Cell Motility.
[7] V. Álvarez,et al. Profile of microRNAs differentially produced in hearts from patients with hypertrophic cardiomyopathy and sarcomeric mutations. , 2011, Clinical chemistry.
[8] H. Watkins,et al. Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. , 2011, Circulation research.
[9] L. Carrier,et al. Cardiac myosin-binding protein C in hypertrophic cardiomyopathy: mechanisms and therapeutic opportunities. , 2011, Journal of molecular and cellular cardiology.
[10] D. Mann,et al. Role of MicroRNAs in Cardiac Remodeling and Heart Failure , 2011, Cardiovascular Drugs and Therapy.
[11] S. Harris,et al. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. , 2011, Circulation research.
[12] E. Paquet,et al. The Journal of Experimental Medicine CORRESPONDENCE , 2005 .
[13] M. Latronico,et al. microRNAs in hypertrophy and heart failure , 2011, Experimental biology and medicine.
[14] G. Condorelli,et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling , 2010, Nature Cell Biology.
[15] David J Beech,et al. Pregnenolone Sulphate- and Cholesterol-Regulated TRPM3 Channels Coupled to Vascular Smooth Muscle Secretion and Contraction , 2010, Circulation research.
[16] E. Olson,et al. MicroRNA regulatory networks in cardiovascular development. , 2010, Developmental cell.
[17] Jian-Fu Chen,et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. , 2009, The Journal of clinical investigation.
[18] C. Ponting,et al. Evolution and Functions of Long Noncoding RNAs , 2009, Cell.
[19] T. Golub,et al. MicroRNA-1 Negatively Regulates Expression of the Hypertrophy-Associated Calmodulin and Mef2a Genes , 2009, Molecular and Cellular Biology.
[20] F. T. ten Cate,et al. Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy: Haploinsufficiency, Deranged Phosphorylation, and Cardiomyocyte Dysfunction , 2009, Circulation.
[21] W. Rottbauer,et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.
[22] W. Paulus,et al. Quantitative analysis of myofilament protein phosphorylation in small cardiac biopsies , 2007, Proteomics. Clinical applications.
[23] Stanley Nattel,et al. Regional and tissue specific transcript signatures of ion channel genes in the non‐diseased human heart , 2007, The Journal of physiology.
[24] C. Croce,et al. MicroRNA-133 controls cardiac hypertrophy , 2007, Nature Medicine.
[25] E. Olson,et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure , 2006, Proceedings of the National Academy of Sciences.
[26] H. Brinkmeier,et al. Tissue-specific expression of TRP channel genes in the mouse and its variation in three different mouse strains , 2006, BMC Genomics.
[27] C. Burge,et al. Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.
[28] V. Regitz-Zagrosek,et al. The 2373insG mutation in the MYBPC3 gene is a founder mutation, which accounts for nearly one-fourth of the HCM cases in the Netherlands. , 2003, European heart journal.
[29] G. Schultz,et al. Molecular and Functional Characterization of the Melastatin-related Cation Channel TRPM3* , 2003, Journal of Biological Chemistry.
[30] Shujian Wu,et al. Expression and Characterization of Human Transient Receptor Potential Melastatin 3 (hTRPM3)* , 2003, Journal of Biological Chemistry.
[31] J. Gardin,et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.
[32] M. Gladka,et al. Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. , 2012, Journal of molecular and cellular cardiology.
[33] Kenneth A Ellenbogen,et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Journal of the American College of Cardiology.
[34] F. T. ten Cate,et al. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. , 2009, JACC. Cardiovascular imaging.
[35] L. McLain,et al. Sudden death in young athletes. , 2003, Pediatric annals.